Abstract
The Smad4/DPC4 tumour suppressor1 is inactivated in nearly half of pancreatic carcinomas2 and to a lesser extent in a variety of other cancers2,3,4. Smad4/DPC4, and the related tumour suppressor Smad2, belong to the SMAD family of proteins that mediate signalling by the TGF-β/activin/BMP-2/4 cytokine superfamily from receptor Ser/Thr protein kinases at the cell surface to the nucleus5,6,7. SMAD proteins, which are phosphorylated by the activated receptor, propagate the signal, in part, through homo- and hetero-oligomeric interactions8,9,10,11,12,13. Smad4/DPC4 plays a central role as it is the shared hetero-oligomerization partner of the other SMADs. The conserved carboxy-terminal domains of SMADs are sufficient for inducing most of the ligand-specific effects, and are the primary targets of tumorigenic inactivation. We now describe the crystal structure of the C-terminal domain (CTD) of the Smad4/DPC4 tumour suppressor, determined at 2.5 Å resolution. The structure reveals that the Smad4/DPC4 CTD forms a crystallographic trimer through a conserved protein–protein interface, to which the majority of the tumour-derived missense mutations map. These mutations disrupt homo-oligomerization in vitro and in vivo, indicating that the trimeric assembly of the Smad4/DPC4 CTD is critical for signalling and is disrupted by tumorigenic mutations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hahn, S. A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350–353 (1996).
Schutte, M. et al. DPC4 gene in various tumor types. Cancer Res. 56, 2527–2530 (1996).
Kim, S. K. et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res. 56, 2519–2521 (1996).
Nagatake, M. et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56, 2718–2720 (1996).
Massague, J. TGF-β signalling: receptors, transducers, and mad proteins. Cell 85, 947–950 (1996).
Derynck, R. et al. Nomenclature: vertebrate mediators of TGFβ family signals. Cell 87, 173 (1996).
Derynck, R. & Zhang, Y. Intracellular signalling: the Mad way to do it. Curr. Biol. 6, 1226–1229 (1996).
Zhang, Y., Feng, X.-H., Wu, R.-Y. & Derynck, R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 383, 168–172 (1996).
Lagna, G., Hata, A., Hemmati-Brivanlou, A. & Massagué, J. Partnership between SPC4 and SMAD proteins in TGF-β signalling pathways. Nature 383, 832–836 (1996).
Yingling, J. M. et al. Mammalian dwarfins are phosphorylated in response to transforming growth factor β and are implicated in control of cell growth. Proc. Natl Acad. Sci. USA 93, 8940–8944 (1996).
Hoodless, P. A. et al. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 85, 489–500 (1996).
Eppert, K. et al. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86, 543–552 (1996).
Lechleider, R. J., de Caestecker, M. P., Dehejia, A., Polymeropoulos, M. H. & Roberts, A. B. Serine phosphorylation, chromosomal localization, and transforming growth factor-β signal transduction by human bsp-1. J. Biol. Chem. 271, 17617–17620 (1996).
Liu, F. et al. Ahuman Mad protein acting as a BMP-regulated transcriptional activator. Nature 381, 620–623 (1996).
Hata, A., Lo, R. S., Wotton, D. & Massagué, J. Mutations increasing autoinhibition inactivate the tumour suppressors Smad2 and Smad4. Nature 388, 82–87 (1997).
Baker, J. C. & Harland, R. M. Anovel mesoderm inducer, Madr2, functions in the activin signal transduction pathway. Genes Dev. 10, 1880–1889 (1996).
Thiagalingam, S. et al. Evaluation of candidate tumour suppressor genes on the chromosome 18 in colorectal cancers. Nature Genet. 13, 343–346 (1996).
Sekelsky, J. J., Newfeld, S. J., Raftery, L. A., Chartoff, E. H. & Gelbart, W. M. Genetic characterization and cloning of Mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 139, 1347–1358 (1995).
Savage, C. et al. Caenorhabditis elegans genes sma-2, sma-3 and sma-4 define a conserved family of transforming growth factor β pathway components. Proc. Natl Acad. Sci. USA 93, 790–794 (1996).
Stura, E. A. & Wilson, I. A. in Crystallization of Nucleic Acids and Proteins(eds Ducruix, A. & Giege, R.) 99–126 (Oxford Univ. Press, (1992)).
Sheldrick, G. in Patterson Interpretation and the Use of Macromolecular Delta-F Data (Daresbury, UK, (1991)).
Collaborative Computational Project, B. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760–763 (1994).
Zhang, K. Y. J. SQUASH-combining constraints for macromolecular phase refinement and extension. Acta Crystallogr. D 49, 213–222 (1993).
Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110–110 (1991).
Brunger, A. T. X-PLOR, a system for crystallography and NMR(Yale Univ. Press, New Haven, CT, (1991)).
Klaulis, P. J. Molscript: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946–950 (1991).
Merrit, E. A. & Murphy, M. E. Raster3D Version 2.0: a program for photorealistic molecular graphics. Acta Crystallogr. D 50, 869–873 (1994).
Uchida, K. et al. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res. 56, 5583–5585 (1996).
Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11, 281–296 (1991).
Macias-Silva, M. et al. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signalling. Cell 87, 1215–1224 (1996).
Acknowledgements
This work was supported by the NIH, the Pew Charitable Trusts, the Arnold and Mabel Beckman Foundation, the Dewitt Wallace Foundation, the Samuel and May Rudin Foundation, and the Howard Hughes Medical Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shi, Y., Hata, A., Lo, R. et al. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388, 87–93 (1997). https://doi.org/10.1038/40431
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/40431
This article is cited by
-
Disruptor: Computational identification of oncogenic mutants disrupting protein-protein and protein-DNA interactions
Communications Biology (2023)
-
PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis
Oncogene (2023)
-
A follicular regulatory Innate Lymphoid Cell population impairs interactions between germinal center Tfh and B cells
Communications Biology (2021)
-
Structural based screening of potential inhibitors of SMAD4: a step towards personalized medicine for gall bladder and other associated cancers
Molecular Diversity (2021)
-
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Journal of Hematology & Oncology (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.